|
G |
CCL2 |
chemokine (C-C motif) ligand 2 |
multiple interactions decreases expression |
EXP |
acetovanillone inhibits the reaction [titanium dioxide results in increased expression of CCL2 mRNA] acetovanillone results in decreased expression of CCL2 mRNA |
CTD |
PMID:23380242 |
|
NCBI chr12:40,798,109...40,800,013
Ensembl chr12:40,798,109...40,800,026
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
acetovanillone inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein] |
CTD |
PMID:24512358 |
|
NCBI chr15:82,967,485...83,146,185
Ensembl chr15:82,973,656...83,146,183
|
|
G |
VCAM1 |
vascular cell adhesion molecule 1 |
multiple interactions |
EXP |
acetovanillone inhibits the reaction [titanium dioxide results in increased expression of VCAM1 mRNA] |
CTD |
PMID:23380242 |
|
NCBI chr 4:117,496,914...117,511,211
Ensembl chr 4:117,496,920...117,511,222
|
|
|
G |
ACO2 |
aconitase 2 |
multiple interactions |
EXP |
Curcumin inhibits the reaction [maleic acid results in decreased activity of ACO2 protein] |
CTD |
PMID:25119790 |
|
NCBI chr 5:7,014,383...7,071,023
Ensembl chr 5:7,008,719...7,071,025
|
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
deguelin results in increased expression of and results in increased phosphorylation of AKT1 protein |
CTD |
PMID:37353039 |
|
|
|
G |
PDK1 |
pyruvate dehydrogenase kinase 1 |
multiple interactions |
EXP |
deguelin results in increased expression of and results in increased phosphorylation of PDK1 protein |
CTD |
PMID:37353039 |
|
NCBI chr15:78,608,394...78,650,958
Ensembl chr15:78,608,432...78,652,962
|
|
G |
PIK3R1 |
phosphoinositide-3-kinase regulatory subunit 1 |
multiple interactions |
EXP |
deguelin results in increased expression of and results in increased phosphorylation of PIK3R1 protein |
CTD |
PMID:37353039 |
|
NCBI chr16:46,434,757...46,523,626
Ensembl chr16:46,511,521...46,523,609
|
|
G |
PTEN |
phosphatase and tensin homolog |
multiple interactions |
EXP |
deguelin results in increased expression of and results in increased phosphorylation of PTEN protein |
CTD |
PMID:37353039 |
|
NCBI chr14:99,929,590...100,021,619
|
|
|
G |
NQO1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP |
Dicumarol inhibits the reaction [sulforaphane inhibits the reaction [Cisplatin results in decreased activity of NQO1 protein]] |
CTD |
PMID:20732396 |
|
NCBI chr 6:17,292,962...17,302,593
Ensembl chr 6:17,292,770...17,302,590
|
|
|
G |
NOS3 |
nitric oxide synthase 3 |
increases expression |
EXP |
Rotenone results in increased expression of NOS3 mRNA |
CTD |
PMID:11382920 |
|
NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943
|
|
|
G |
BMP2 |
bone morphogenetic protein 2 |
multiple interactions increases expression |
EXP |
[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of BMP2 mRNA; [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of BMP2 protein; leptomycin B inhibits the reaction [Warfarin results in increased expression of BMP2 mRNA]; LRP6 protein affects the reaction [SOX5 protein inhibits the reaction [Warfarin results in increased expression of BMP2 mRNA]]; LRP6 protein affects the reaction [Warfarin results in increased expression of BMP2 mRNA]; SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of BMP2 mRNA]; SOX5 protein inhibits the reaction [Warfarin results in increased expression of BMP2 mRNA] |
CTD |
PMID:29358327 PMID:34520801 |
|
NCBI chr17:15,750,487...15,762,982
Ensembl chr17:15,749,835...15,761,195
|
|
G |
CDKN1A |
cyclin dependent kinase inhibitor 1A |
multiple interactions |
EXP |
[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of CDKN1A protein |
CTD |
PMID:29358327 |
|
NCBI chr 7:32,354,776...32,363,771
Ensembl chr 7:32,359,455...32,363,761
|
|
G |
EP300 |
E1A binding protein p300 |
multiple interactions |
EXP |
[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of EP300 protein |
CTD |
PMID:29358327 |
|
NCBI chr 5:7,311,165...7,394,515
Ensembl chr 5:7,311,171...7,393,760
|
|
G |
LRP6 |
LDL receptor related protein 6 |
multiple interactions increases expression |
EXP |
LRP6 protein affects the reaction [SOX5 protein inhibits the reaction [Warfarin results in increased expression of BMP2 mRNA]]; LRP6 protein affects the reaction [SOX5 protein inhibits the reaction [Warfarin results in increased expression of RUNX2 mRNA]]; LRP6 protein affects the reaction [Warfarin results in increased expression of BMP2 mRNA]; LRP6 protein affects the reaction [Warfarin results in increased expression of RUNX2 mRNA]; SOX5 protein promotes the reaction [Warfarin promotes the reaction [SOX9 protein binds to LRP6 promoter]]; SOX5 protein promotes the reaction [Warfarin results in increased expression of LRP6 protein]; Warfarin promotes the reaction [SOX9 protein binds to LRP6 promoter] Warfarin results in increased expression of LRP6 mRNA; Warfarin results in increased expression of LRP6 protein |
CTD |
PMID:34520801 |
|
NCBI chr 5:60,149,041...60,318,719
Ensembl chr 5:60,149,028...60,314,662
|
|
G |
RUNX2 |
RUNX family transcription factor 2 |
multiple interactions increases expression |
EXP |
[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 mRNA; [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 protein; Ammonium Chloride inhibits the reaction [SOX5 protein inhibits the reaction [Warfarin results in increased expression of RUNX2 mRNA]]; LRP6 protein affects the reaction [SOX5 protein inhibits the reaction [Warfarin results in increased expression of RUNX2 mRNA]]; LRP6 protein affects the reaction [Warfarin results in increased expression of RUNX2 mRNA]; SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 mRNA]; SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 protein]; SOX5 protein inhibits the reaction [Warfarin promotes the reaction [SOX9 protein binds to RUNX2 promoter]]; SOX5 protein inhibits the reaction [Warfarin results in increased expression of RUNX2 mRNA]; SOX5 protein inhibits the reaction [Warfarin results in increased expression of RUNX2 protein]; Warfarin promotes the reaction [SOX9 protein binds to RUNX2 promoter] Warfarin results in increased expression of RUNX2 mRNA; Warfarin results in increased expression of RUNX2 protein |
CTD |
PMID:29358327 PMID:34520801 |
|
NCBI chr 7:40,106,581...40,353,304
Ensembl chr 7:40,106,532...40,460,687
|
|
G |
SNAI2 |
snail family transcriptional repressor 2 |
multiple interactions |
EXP |
[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of SNAI2 protein; SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of BMP2 mRNA]; SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 mRNA]; SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 protein]; SNAI2 protein promotes the reaction [TP53 protein results in increased susceptibility to Warfarin]; Warfarin promotes the reaction [TP53 protein binds to SNAI2 promoter] |
CTD |
PMID:29358327 |
|
NCBI chr 4:79,264,880...79,268,475
Ensembl chr 4:79,264,880...79,268,475
|
|
G |
SOX5 |
SRY-box transcription factor 5 |
decreases expression multiple interactions |
EXP |
Warfarin results in decreased expression of SOX5 mRNA Ammonium Chloride inhibits the reaction [SOX5 protein inhibits the reaction [Warfarin results in increased expression of RUNX2 mRNA]]; LRP6 protein affects the reaction [SOX5 protein inhibits the reaction [Warfarin results in increased expression of BMP2 mRNA]]; LRP6 protein affects the reaction [SOX5 protein inhibits the reaction [Warfarin results in increased expression of RUNX2 mRNA]]; SOX5 protein affects the reaction [Warfarin results in decreased expression of SOX9 mRNA]; SOX5 protein inhibits the reaction [Warfarin promotes the reaction [SOX9 protein binds to RUNX2 promoter]]; SOX5 protein inhibits the reaction [Warfarin results in decreased expression of and affects the localization of SOX9 protein]; SOX5 protein inhibits the reaction [Warfarin results in increased expression of BMP2 mRNA]; SOX5 protein inhibits the reaction [Warfarin results in increased expression of RUNX2 mRNA]; SOX5 protein inhibits the reaction [Warfarin results in increased expression of RUNX2 protein]; SOX5 protein promotes the reaction [Warfarin promotes the reaction [SOX9 protein binds to LRP6 promoter]]; SOX5 protein promotes the reaction [Warfarin results in increased expression of LRP6 protein]; Warfarin promotes the reaction [SOX5 protein binds to SOX9 promoter]; Warfarin results in decreased expression of and affects the localization of SOX5 protein |
CTD |
PMID:34520801 |
|
NCBI chr 5:49,159,950...50,166,463
Ensembl chr 5:49,504,551...50,161,558
|
|
G |
SOX9 |
SRY-box transcription factor 9 |
multiple interactions decreases expression |
EXP |
SOX5 protein affects the reaction [Warfarin results in decreased expression of SOX9 mRNA]; SOX5 protein inhibits the reaction [Warfarin promotes the reaction [SOX9 protein binds to RUNX2 promoter]]; SOX5 protein inhibits the reaction [Warfarin results in decreased expression of and affects the localization of SOX9 protein]; SOX5 protein promotes the reaction [Warfarin promotes the reaction [SOX9 protein binds to LRP6 promoter]]; Warfarin promotes the reaction [SOX5 protein binds to SOX9 promoter]; Warfarin promotes the reaction [SOX9 protein binds to LRP6 promoter]; Warfarin promotes the reaction [SOX9 protein binds to RUNX2 promoter]; Warfarin results in decreased expression of and affects the localization of SOX9 protein |
CTD |
PMID:34520801 |
|
NCBI chr12:8,642,154...8,647,315
Ensembl chr12:8,642,158...8,647,315
|
|
G |
TP53 |
tumor protein p53 |
increases response to substance increases expression multiple interactions |
EXP |
TP53 protein results in increased susceptibility to Warfarin Warfarin results in increased expression of TP53 mRNA [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of BMP2 mRNA; [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of BMP2 protein; [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of CDKN1A protein; [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of EP300 protein; [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 mRNA; [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 protein; [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of SNAI2 protein; SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of BMP2 mRNA]; SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 mRNA]; SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 protein]; SNAI2 protein promotes the reaction [TP53 protein results in increased susceptibility to Warfarin]; Warfarin promotes the reaction [TP53 protein binds to SNAI2 promoter]; Warfarin results in increased expression of and results in decreased acetylation of TP53 protein |
CTD |
PMID:29358327 |
|
NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,644...52,953,818
|
|